Sign in

Howard

Principal Equity Analyst at Taglich Brothers

Howard Halpern is a Principal Equity Analyst at Taglich Brothers, specializing in micro-cap healthcare and pharmaceutical companies. He has provided coverage for firms such as Cosmos Health Inc. and Trxade Group, assigning ratings and price targets that have often prompted strong market attention, including a 12-month price target nearly five times higher than Cosmos Health’s then-current share price. Halpern began his analyst work prior to 2015 and continues his sector focus at Taglich Brothers, leveraging extensive equity research experience. He maintains professional credentials typical for his role, including full disclosure per FINRA standards and a focus on institutional-grade analysis.

Howard's questions to Banzai International (BNZI) leadership

Howard's questions to Banzai International (BNZI) leadership • Q2 2025

Question

Howard from Taglich asked about the typical sales cycle for Banzai's mid-market and enterprise customers, the expected timeline for the new sales team to drive sequential revenue growth, and the potential for continued reduction in operating expenses.

Answer

CEO Joe Davy explained that sales cycles range from 30-60 days for mid-market to over a year for large enterprises. He noted the new sales leadership is already making progress. Davy prioritized reducing the cost of capital over OpEx cuts for bottom-line impact, while CFO Dean Ditto added that the company is finding cost efficiencies from recent acquisitions but will also invest selectively in resources to support growth.

Ask Fintool Equity Research AI

Howard's questions to Banzai International (BNZI) leadership • Q2 2025

Question

Howard from Taglich Brothers asked about Banzai's sales cycle for mid-market and enterprise customers, the expected timeline for the new sales team to drive sequential revenue growth, and the potential for continued reductions in operating expenses.

Answer

CEO Joe Davy explained that sales cycles range from 30-60 days for mid-market to over a year for large enterprises, noting the new sales team is already making progress. Davy prioritized reducing the cost of capital over OpEx cuts for bottom-line impact. CFO Dean Ditto added that while the company is finding cost efficiencies, it will also selectively invest in resources to support its growth phase.

Ask Fintool Equity Research AI